A carregar...
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
PURPOSE: Intravitreal anti-vascular endothelial growth factor (VEGF) agents are effective in the treatment of central involving diabetic macular oedema (DMO). Vitreoretinal interface abnormalities (VRIA) are common in patients with DMO, and the effect of these on the response to anti-VEGF treatment...
Na minha lista:
| Publicado no: | Graefes Arch Clin Exp Ophthalmol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Berlin Heidelberg
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5364245/ https://ncbi.nlm.nih.gov/pubmed/27957600 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00417-016-3562-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|